APGE vs. GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, TGTX, and CRSP
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry.
Apogee Therapeutics vs. Its Competitors
Apogee Therapeutics (NASDAQ:APGE) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.
Apogee Therapeutics presently has a consensus target price of $92.63, suggesting a potential upside of 133.58%. Grifols has a consensus target price of $10.30, suggesting a potential upside of 5.91%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Apogee Therapeutics is more favorable than Grifols.
Apogee Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
79.0% of Apogee Therapeutics shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Grifols' return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Grifols has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
In the previous week, Apogee Therapeutics had 1 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Apogee Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 1.04 beat Apogee Therapeutics' score of 0.66 indicating that Grifols is being referred to more favorably in the news media.
Summary
Grifols beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APGE) was last updated on 10/6/2025 by MarketBeat.com Staff
